Protagonist Therapeutics is skyrocketing today and for good reason. The ANTHEM-UC Phase 2b study of icotrokinra is complete, and the results are more than promising. This one will pay off for those who took the risk. The Phase 3 study is all but guaranteed to confirm what’s already been determined and keep the stock soaring. I'm a happy camper today.
There are no replies in this thread yet. Be the first to post a reply below: